Research
Cell Therapy for Knee Osteoarthritis Reverses Damage in Early Trial
The Brief
- OSCA, a cell-based therapy for knee osteoarthritis, improved patients' symptoms in a phase IIa trial and appeared safe.
- Researchers reported signs that the therapy reverses joint damage within a few months.
- The results were presented at a meeting in Orlando, as reported by MedPage Today.
Why it matters
If confirmed in larger, controlled trials, a cell therapy that repairs rather than only eases knee osteoarthritis would change treatment options for a very common joint disease. The current evidence comes from an early-phase trial.
Who’s affected
- patients with knee osteoarthritis
- rheumatologists and orthopedic clinicians
- researchers in regenerative medicine and cell therapy
- #knee osteoarthritis
- #cell therapy
- #clinical trial
- #regenerative medicine
(MedPage Today) -- ORLANDO -- A cell-based therapy for knee osteoarthritis (OA) called OSCA not only improved patients' symptoms in a phase IIa trial and appeared safe, but also showed signs of reversing joint damage within a few months, a researcher...